Sugi Predict

Sugi Predict / Compounds / SCHEMBL578540

SCHEMBL578540

SCHEMBL578540

CN1CCN(c2ccc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR3A P46098 3/20 0.42
▸ HRH4 Q9H3N8 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ DGAT1 O75907 2/20 0.38
▸ LPL P06858 1/20 0.37
▸ LIPG Q9Y5X9 1/20 0.37
▸ HRH3 Q9Y5N1 2/20 0.37
▸ HTR3E A5X5Y0 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ HTR3B O95264 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ THPO P40225 1/20 0.37
▸ HTR3D Q70Z44 1/20 0.37
▸ HTR3C Q8WXA8 1/20 0.37
▸ TDO2 P48775 1/20 0.37
▸ FYN P06241 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29542633 1.00 HTR3A (0.42) HTR3AHRH4RAB9AL3MBTL1KMT2A
SCHEMBL3606878 0.95 HTR3A (0.39) HTR3AHRH4RAB9AL3MBTL1KMT2A
SCHEMBL2068884 0.88 MAPT (0.41) KMT2ADGAT1LPLLIPGKDM4E
SCHEMBL1484906 0.88 MAPT (0.44) DGAT1LPLLIPGALDH1A1SMN1; SMN2
SCHEMBL29378036 0.88 MAPT (0.44) DGAT1LPLLIPGALDH1A1SMN1; SMN2
SCHEMBL1330752 0.87 MAPT (0.46) DGAT1LPLLIPGALDH1A1SMN1; SMN2
SCHEMBL29377874 0.87 MAPT (0.46) DGAT1LPLLIPGALDH1A1SMN1; SMN2
SCHEMBL31212828 0.86 ALDH1A1 (0.49) KMT2AKDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL142528 0.86 ALDH1A1 (0.49) KMT2AKDM4EALDH1A1CYP1A2SMN1; SMN2
SCHEMBL25198792 0.85 LPL (0.40) DGAT1LPLLIPGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113527275-A SKLB1039 compound and preparation method and application thereof 成都师范学院 2021-10-22 — — CN claimed
EP-4696316-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 — — EP disclosed
US-20260042740-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-12 — — US disclosed
EP-4054719-B1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-11 — — EP disclosed
US-12516059-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2026-01-06 — — US disclosed
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2025-12-25 — — US disclosed
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof INCYTE CORPORATION (US) 2025-10-14 — — US disclosed
US-12384750-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-08-12 — — US disclosed
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 — — US disclosed
WO-2025064853-A1 RIPK3 INHIBITORS AND METHODS OF USE Momentum Therapeutics, Inc. (US) 2025-03-27 — — WO disclosed
WO-2008150446-A1 INHIBITORS OF PROTEIN KINASES LIANG CONGXIN (US) 2008-12-11 — — WO disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 — — US disclosed
WO-2008089052-A2 N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 — — WO disclosed
EP-1934223-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 Novartis Pharma AG (CH) 2008-06-25 — — EP disclosed
WO-2008034600-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES NOVARTIS AG (CH) 2008-03-27 — — WO disclosed
US-20080032972-A1 Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors CEPHALON, INC. (US) 2008-02-07 — — US disclosed
WO-2007130468-A2 PYRIDO [2, 3-B] PYRAZINE AND [1, 8] -NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS CEPHALON, INC. (US) 2007-11-15 — — WO disclosed
WO-2007039285-A1 BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 NOVARTIS AG (CH) 2007-04-12 — — WO disclosed
WO-2007002325-A1 PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 — — WO disclosed
WO-2007002433-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384778-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 HTR3A 2392/4885HRH4 742/4885RAB9A 2324/4885
US-20260042740-A1 RAS INHIBITORS KRAS, NRAS, HRAS HTR3A 4604/4885HRH4 2326/4885RAB9A 22/4885
US-12441731-B2 Pyrazolopyrimidine compounds and uses thereof ALK, FGFR1, FGFR2 HTR3A 4433/4885HRH4 2128/4885RAB9A 3822/4885
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN HTR3A 1758/4885HRH4 406/4885RAB9A 4437/4885
US-20080032972-A1 Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors ALK, MET, RET HTR3A 968/4885HRH4 325/4885RAB9A 3149/4885
US-12384750-B2 Ras inhibitors KRAS, NRAS, HRAS HTR3A 4714/4885HRH4 3624/4885RAB9A 37/4885
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE PIK3C2B, PIK3C2A, PIK3R1 HTR3A 2248/4885HRH4 1644/4885RAB9A 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.